ChartMill · Mar 9, 2026
Myomo Inc (NYSEARCA:MYO) Reports Mixed Q4 Results Amid Strategic Shift
Myomo beats Q4 revenue estimates but widens loss, prioritizing a strategic shift to recurring revenue channels over short-term profitability.
NYSE · MYO
Healthcare · Medical - Devices
$1.30
Up+$0.00 (+0.00%)
Updated Sep 11, 2026, 2:24 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
MYO closed at $1.30 after 20 trading sessions, down 10.96% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $1.31 | $1.375 | $1.295 | $1.30 | 234.35K |
| Sep 9, 2026 | $1.35 | $1.37 | $1.31 | $1.33 | 190.25K |
| Sep 8, 2026 | $1.41 | $1.46 | $1.33 | $1.34 | 434.67K |
| Sep 4, 2026 | $1.41 | $1.455 | $1.38 | $1.44 | 378.68K |
| Sep 3, 2026 | $1.45 | $1.49 | $1.36 | $1.40 | 538.6K |
| Sep 2, 2026 | $1.44 | $1.48 | $1.35 | $1.41 | 394.09K |
| Sep 1, 2026 | $1.48 | $1.5317 | $1.43 | $1.43 | 236.64K |
| Aug 31, 2026 | $1.55 | $1.6426 | $1.47 | $1.49 | 517.68K |
| Aug 28, 2026 | $1.65 | $1.66 | $1.57 | $1.60 | 313.93K |
| Aug 27, 2026 | $1.56 | $1.68 | $1.535 | $1.66 | 546.37K |
| Aug 26, 2026 | $1.47 | $1.55 | $1.4001 | $1.53 | 373.87K |
| Aug 25, 2026 | $1.38 | $1.50 | $1.38 | $1.48 | 820.35K |
| Aug 24, 2026 | $1.70 | $1.75 | $1.36 | $1.39 | 934.56K |
| Aug 21, 2026 | $1.75 | $1.79 | $1.56 | $1.73 | 1.09M |
| Aug 20, 2026 | $1.86 | $1.86 | $1.685 | $1.74 | 897.57K |
| Aug 19, 2026 | $1.72 | $1.885 | $1.69 | $1.86 | 1.08M |
| Aug 18, 2026 | $1.58 | $1.695 | $1.52 | $1.68 | 732.14K |
| Aug 17, 2026 | $1.65 | $1.80 | $1.57 | $1.57 | 860.92K |
| Aug 14, 2026 | $1.44 | $1.77 | $1.42 | $1.72 | 1.43M |
| Aug 13, 2026 | $1.48 | $1.55 | $1.45 | $1.46 | 591.18K |
The latest Smart Investors Daily articles mentioning MYO.
MYO research
Company profile and research snapshot.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 27, 2026 | Ascendiant Capital | Buy | — |
| Jun 8, 2026 | Ascendiant Capital | Buy | — |
| Sep 22, 2025 | Ascendiant Capital | Buy | — |
| Aug 12, 2025 | HC Wainwright & Co. | Buy | — |
| Jun 23, 2025 | Craig-Hallum | Buy | — |
No generated briefing is available yet.
ChartMill · Mar 9, 2026
Myomo beats Q4 revenue estimates but widens loss, prioritizing a strategic shift to recurring revenue channels over short-term profitability.
SeekingAlpha · Mar 9, 2026
Myomo, Inc. (MYO) Q4 2025 Earnings Call March 9, 2026 4:30 PM EDTCompany ParticipantsPaul Gudonis - President, CEO & ChairmanDavid Henry - Chief...
Benzinga · Mar 9, 2026
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced today it has
Benzinga · Mar 9, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning MYO.